比较他喷他多与其他阿片类药物的药理镇痛反应和安全性。

IF 1.5 4区 医学 Q4 CHEMISTRY, MEDICINAL Pharmazie Pub Date : 2024-10-01 DOI:10.1691/ph.2024.4591
D Krtinic, G N Rankovic, A Cvetanovic, I Conic, M Todorovic Mitic, M Radic, A Lucic Prokin, M Cevrljakovic
{"title":"比较他喷他多与其他阿片类药物的药理镇痛反应和安全性。","authors":"D Krtinic, G N Rankovic, A Cvetanovic, I Conic, M Todorovic Mitic, M Radic, A Lucic Prokin, M Cevrljakovic","doi":"10.1691/ph.2024.4591","DOIUrl":null,"url":null,"abstract":"<p><p>Tapentadol is a unique opioid analgesic due to its dual mechanism of action. Compared to other opioids with a classical mechanism of action, its analgesic potential is not far behind them, and its advantages are: a better safety profile in terms of a lower potential for drug-drug interactions and a lower potential for causing adverse events, and it is safe to use in sensitive populations. Tapentadol in the form of a immediate release formulation is an adequate drug of choice for achieving a pharmacotherapeutic analgesic response in acute pain conditions, while in the form of a extended release formulation it is an adequate pharmacotherapeutic analgesic solution for chronic pain syndromes of various etiology. Due to the specificity of the mechanism of action, tapentadol adequately relieves both pain components - nociceptive and neuropathic, and has an indication area for mixed pain syndrome as well. Based on this, the need for the use of co-analgesics is reduced, and thus the incidence of possible interactions and adverse events is reduced.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"179-183"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids.\",\"authors\":\"D Krtinic, G N Rankovic, A Cvetanovic, I Conic, M Todorovic Mitic, M Radic, A Lucic Prokin, M Cevrljakovic\",\"doi\":\"10.1691/ph.2024.4591\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tapentadol is a unique opioid analgesic due to its dual mechanism of action. Compared to other opioids with a classical mechanism of action, its analgesic potential is not far behind them, and its advantages are: a better safety profile in terms of a lower potential for drug-drug interactions and a lower potential for causing adverse events, and it is safe to use in sensitive populations. Tapentadol in the form of a immediate release formulation is an adequate drug of choice for achieving a pharmacotherapeutic analgesic response in acute pain conditions, while in the form of a extended release formulation it is an adequate pharmacotherapeutic analgesic solution for chronic pain syndromes of various etiology. Due to the specificity of the mechanism of action, tapentadol adequately relieves both pain components - nociceptive and neuropathic, and has an indication area for mixed pain syndrome as well. Based on this, the need for the use of co-analgesics is reduced, and thus the incidence of possible interactions and adverse events is reduced.</p>\",\"PeriodicalId\":20145,\"journal\":{\"name\":\"Pharmazie\",\"volume\":\"79 9\",\"pages\":\"179-183\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmazie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1691/ph.2024.4591\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1691/ph.2024.4591","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

由于具有双重作用机制,他喷他多是一种独特的阿片类镇痛药。与其他具有经典作用机制的阿片类药物相比,它的镇痛潜力并不逊色,其优势在于:安全性更好,药物间相互作用的可能性更低,引起不良反应的可能性更低,而且在敏感人群中使用也很安全。速释剂型的他喷他多是在急性疼痛情况下实现药物治疗镇痛反应的理想选择,而缓释剂型的他喷他多则是各种病因引起的慢性疼痛综合征的理想药物治疗镇痛解决方案。由于其作用机制的特异性,他喷他多能充分缓解两种疼痛--痛觉性疼痛和神经病理性疼痛,也是混合性疼痛综合症的适应症。在此基础上,减少了使用联合镇痛剂的需要,从而降低了可能发生的相互作用和不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids.

Tapentadol is a unique opioid analgesic due to its dual mechanism of action. Compared to other opioids with a classical mechanism of action, its analgesic potential is not far behind them, and its advantages are: a better safety profile in terms of a lower potential for drug-drug interactions and a lower potential for causing adverse events, and it is safe to use in sensitive populations. Tapentadol in the form of a immediate release formulation is an adequate drug of choice for achieving a pharmacotherapeutic analgesic response in acute pain conditions, while in the form of a extended release formulation it is an adequate pharmacotherapeutic analgesic solution for chronic pain syndromes of various etiology. Due to the specificity of the mechanism of action, tapentadol adequately relieves both pain components - nociceptive and neuropathic, and has an indication area for mixed pain syndrome as well. Based on this, the need for the use of co-analgesics is reduced, and thus the incidence of possible interactions and adverse events is reduced.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmazie
Pharmazie 医学-化学综合
CiteScore
3.10
自引率
0.00%
发文量
56
审稿时长
1.2 months
期刊介绍: The journal DiePharmazie publishs reviews, experimental studies, letters to the editor, as well as book reviews. The following fields of pharmacy are covered: Pharmaceutical and medicinal chemistry; Pharmaceutical analysis and drug control; Pharmaceutical technolgy; Biopharmacy (biopharmaceutics, pharmacokinetics, biotransformation); Experimental and clinical pharmacology; Pharmaceutical biology (pharmacognosy); Clinical pharmacy; History of pharmacy.
期刊最新文献
Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort. Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids. Cross-reactivity of triptans and sulfonamide antibiotics - a clinically relevant question? Impact of medication reconciliation and medication reviews on the incidence of preventable adverse drug reactions during hospitalization of elderly patients. A randomized controlled trial. Potential effects of attention deficit hyperactivity disorder medication on body height and body weight in a longitudinal pediatric cohort study, the LIFE Child study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1